These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1067 related items for PubMed ID: 19887966

  • 1. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C, Barrera D, Jotte R, Spira AI, Weissman C, Boehm KA, Pritchard S, Asmar L.
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD, Mace J, Mandanas RA, Min M, Olsen M, Youssoufian H, Katz TL, Sheth G, Lee HJ.
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [Abstract] [Full Text] [Related]

  • 3. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
    Paz-Ares L, Bálint B, de Boer RH, van Meerbeeck JP, Wierzbicki R, De Souza P, Galimi F, Haddad V, Sabin T, Hei YJ, Pan Y, Cottrell S, Hsu CP, RamLau R.
    J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
    [Abstract] [Full Text] [Related]

  • 4. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
    Cohen EE, Subramanian J, Gao F, Szeto L, Kozloff M, Faoro L, Karrison T, Salgia R, Govindan R, Vokes EE.
    Clin Lung Cancer; 2012 Mar; 13(2):123-8. PubMed ID: 22100149
    [Abstract] [Full Text] [Related]

  • 5. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
    Cohen MH, Gootenberg J, Keegan P, Pazdur R.
    Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.
    Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA.
    Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189
    [Abstract] [Full Text] [Related]

  • 8. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
    Hata A, Katakami N, Tanaka K, Takeshita J, Matsumoto T, Monden K, Nagata K, Masago K, Kaji R, Fujita S, Tachikawa R, Otsuka K, Otsuka K, Tomii K.
    Anticancer Res; 2014 Jan; 34(1):275-81. PubMed ID: 24403474
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
    Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J.
    J Thorac Oncol; 2008 Nov; 3(11):1286-92. PubMed ID: 18978564
    [Abstract] [Full Text] [Related]

  • 11. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
    Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF.
    J Clin Oncol; 2012 Jun 10; 30(17):2055-62. PubMed ID: 22547591
    [Abstract] [Full Text] [Related]

  • 12. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
    Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C.
    J Thorac Oncol; 2011 Jan 10; 6(1):109-14. PubMed ID: 21107290
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
    Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF.
    J Thorac Oncol; 2010 Mar 10; 5(3):354-60. PubMed ID: 20032789
    [Abstract] [Full Text] [Related]

  • 14. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
    Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P.
    J Thorac Oncol; 2015 Feb 10; 10(2):353-9. PubMed ID: 25611228
    [Abstract] [Full Text] [Related]

  • 15. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y, Satouchi M, Shimada T, Urata Y, Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, Fujita S, Kaji R, Hata A, Tachihara M, Morita S, Negoro S.
    Lung Cancer; 2015 Feb 10; 87(2):136-40. PubMed ID: 25553650
    [Abstract] [Full Text] [Related]

  • 16. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ.
    J Clin Oncol; 2008 Jan 20; 26(3):468-73. PubMed ID: 18202422
    [Abstract] [Full Text] [Related]

  • 17. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
    Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH, Eastern Cooperative Oncology Group.
    J Clin Oncol; 2008 Jan 01; 26(1):60-5. PubMed ID: 18165641
    [Abstract] [Full Text] [Related]

  • 18. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
    Urata Y, Okamoto I, Takeda M, Hattori Y, Okuno K, Shimada T, Kurata T, Kaneda H, Miyazaki M, Terashima M, Tanaka K, Morita S, Nakagawa K, Negoro S, Satouchi M.
    Cancer; 2013 Jun 15; 119(12):2275-81. PubMed ID: 23558513
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.
    Spigel DR, Anthony Greco F, Waterhouse DM, Shipley DL, Zubkus JD, Bury MJ, Webb CD, Hart LL, Gian VG, Infante JR, Burris HA, Hainsworth JD.
    Lung Cancer; 2012 Oct 15; 78(1):70-5. PubMed ID: 22947511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.